Study of Axitinib and Temsirolimus in Solid Tumors
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine the highest safe dose of the combination of
temsirolimus and axitinib; to learn the side effects when these drugs are given together; and
to determine how the patient's disease responds to treatment.
The combination of the drugs temsirolimus and axitinib has not been studied before so it is
unknown whether this treatment will have any benefit in the patient's cancer.
Temsirolimus is commercially available and approved for treatment of some types of kidney
cancer.
Axitinib has been tested in several diseases but it is not yet commercially available for the
treatment of any cancer in the United States.
The combination of temsirolimus and axitinib is not approved for treatment of any cancer
outside of a clinical trial.